We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Clinical Trial Length Determines Drug Thresholds
FDA: Clinical Trial Length Determines Drug Thresholds
January 21, 2009
The FDA is setting different thresholds for drugs in clinical development based on the length of time they will be administered to patients in trials, according to a draft guidance from the agency on acceptable limits for genotoxic and carcinogenic impurities.